This federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the discovery of noncanonical antigens in triple-negative breast cancer to develop novel T cell therapies. The $505,071 award was made on February 15, 2025 to the University of Texas MD Anderson Cancer Center, and has an ultimate completion date of February 14, 2028. The MD Anderson Cancer Center, a prominent cancer research institution, will conduct this project to advance therapeutic approaches for this challenging breast cancer subtype. The federal grant program supports a range of biomedical research initiatives aimed at improving health outcomes for military service members, veterans, and the broader public.
Generated 3/4/25, 5:41 AM